Evidence map›Paper›PMID 25445179›Full record

ArticleCurrent protocols in chemical biology2014

Determination of the cytostatic and cytocidal activities of antimalarial compounds and their combination interactions.

Katy S Sherlach, Paul D Roepe

Abstract read
In one paragraph

Article in Current protocols in chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Katy S SherlachDepartment of Chemistry and Department of Biochemistry and Cellular and Molecular Biology, Georgetown University, Washington, D.C.
Paul D RoepeDepartment of Chemistry and Department of Biochemistry and Cellular and Molecular Biology, Georgetown University, Washington, D.C.

Funding

The Function of Antimalarial Drug Resistance ProteinsR01AI056312 · NIAID · GEORGETOWN UNIVERSITY · PI PAUL D. ROEPE · 2003 to 2026
$7.5M
Optimized Combination Antimalarial Drug TherapyR01AI111962 · NIAID · GEORGETOWN UNIVERSITY · PI ROEPE, PAUL D., SULLIVAN, DAVID JOSEPH · 2014 to 2018
$4.9M
THE PHYSIOLOGY OF DRUG RESISTANT MALARIAR01AI045957 · NIAID · GEORGETOWN UNIVERSITY · PI ROEPE, PAUL D. · 2000 to 2009
$1.9M
NIAID NIH HHS AI045957NIAID NIH HHS AI056312NIAID NIH HHS R01 AI045957NIAID NIH HHS R01 AI056312NIAID NIH HHS R01 AI111962
6 · The paper itself

Abstract

Determining the antiplasmodial activity of candidate antimalarial drugs in vitro identifies new therapies for drug-resistant malaria. Importantly though, activity can be either growth-inhibitory (cytostatic) or parasite-kill (cytocidal), or both. The simple methods described here can allow for distinction between these activities, as well as definition of drug interactions between two or more compounds. The latter is important in the definition of novel drug combination therapy for malaria. These methods involve live malarial parasite red blood cell culture, routine pharmacology, high-throughput detection of parasite DNA with fluorescent reporters, and routine mathematical analysis of dose-response curves. The techniques and approaches are accessible to most laboratories and require minimal special equipment beyond a fluorescent plate reader and tissue culture facilities.

Indexed as

AntimalarialsCytostatic AgentsDNA, ProtozoanDrug SynergismErythrocytesFluorescenceInhibitory Concentration 50Lethal Dose 50Parasitic Sensitivity TestsPlasmodium falciparumAntimalarialsCytostatic AgentsDNA, Protozoanantiplasmodial activitycytocidalcytostaticdrug combination analysisPlasmodium falciparum

Identifiers

PMID25445179
PMCPMC4282141

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.